Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) is a publicly traded Healthcare sector company. As of May 21, 2026, CUPR trades at $0.25 with a market cap of $5.95M and a P/E ratio of 0.00. CUPR moved -4.10% today. Year to date, CUPR is -39.73%; over the trailing twelve months it is -93.98%. Its 52-week range spans $0.22 to $9.50. Rallies surfaces CUPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cuprina Gains SFDA Classification for MEDIFLY, Names Dr. Enming Yong: Cuprina's 49%-owned MENA unit secured SFDA classification for MEDIFLY as a Medical Device–Drug combination product, clearing scientific and technical requirements for commercial distribution across Saudi Arabia's healthcare system. It also appointed endocrinologist Enming Yong to its Scientific Advisory Board for protocol review, clinical oversight and strategic development.
| Metric | Value |
|---|---|
| Price | $0.25 |
| Market Cap | $5.95M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.50 |
| 52-Week Low | $0.22 |
| Volume | 5.02K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
CUPR analyst coverage data. Average price target: $0.00.